US 7,582,296 B2
	Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
Jean Guy G. Gilles, Brussels (Belgium); Jean-Marie R. Saint-Remy, Grez-Doiceau (Belgium); and Marc G. Jacquemin, Sart-Bernard (Belgium)
Assigned to D. Collen Research Foundation VZW, Leuven (Belgium)
Appl. No. 10/523,444 PCT Filed Jul. 28, 2003, PCT No. PCT/EP03/08365 § 371(c)(1), (2), (4) Date Jan. 31, 2005, PCT Pub. No. WO2004/014955, PCT Pub. Date Feb. 19, 2004.
Claims priority of application No. 02447150 (EP), filed on Jul. 31, 2002.
Prior Publication US 2006/0239998 A1, Oct. 26, 2006
Int. Cl. A61K 39/395 (2006.01)

U.S. Cl. 424—131.1  [424/133.1; 424/141.1; 424/145.1; 435/7.1; 435/327; 530/387.2; 530/387.3; 530/388.1; 530/388.25]

20 Claims

1. A monoclonal anti-idiotypic antibody capable of neutralising a human Factor VIII inhibitory antibody, the said inhibitory antibody being directed towards the C2 domain of Factor VIII, characterized by the fact that the complementary determining regions CDR1, CDR2, and CDR3 of the variable heavy chains of said anti-idiotypic antibody have amino acid sequences depicted in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively and the complementary determining regions CDR1, CDR2, and CDR3 of the variable light chains of said anti-idiotypic antibody have amino acid sequences depicted in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively.